登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05623982,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Patients with histologically confirmed non-Hodgkin's lymphoma;
入选标准第 5 条
Adverse reactions from prior anti-tumor treatment have recovered to ≤Grade 1 as per CTCAE 5.0 criteria;
入选标准第 9 条
Female subjects of childbearing potential or male subjects with partners of childbearing potential must use highly effective contraception from 7 days before the first dose until 12 weeks after treatment discontinuation. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose;
入选标准第 11 条
Chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives prior to treatment;
排除标准第 17 条
ECOG performance status score ≤2;
入选标准第 8 条
Presence of measurable lesions during the screening period (lymph node lesions with any long diameter ≥1.5 cm or extranodal lesions with any long diameter >1.0 cm);
入选标准第 7 条
History of other malignancies within 5 years prior to the first dose;
排除标准第 5 条
HBsAg-positive and/or HBcAb-positive with HBV-DNA levels ≥ the lower limit of detection; HCV antibody-positive with HCV-RNA levels ≥ the lower limit of detection; HIV antibody-positive;
排除标准第 6 条
Pregnant or lactating women;
排除标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05623982,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
The subject is capable of understanding the informed consent form, voluntarily participates, and signs the informed consent form; No gender restrictions; Age: ≥18 years and ≤75 years; Expected survival time ≥3 months; Patients with histologically confirmed non-Hodgkin's lymphoma; Patients with relapsed or refractory non-Hodgkin's lymphoma (R/R NHL); Presence of measurable lesions during the screening period (lymph node lesions with any long diameter ≥1.5 cm or extranodal lesions with any long diameter >1.0 cm); ECOG performance status score ≤2; Adverse reactions from prior anti-tumor treatment have recovered to ≤Grade 1 as per CTCAE 5.0 criteria; Organ function levels meet the requirements before the first dose; Female subjects of childbearing potential or male subjects with partners of childbearing potential must use highly effective contraception from 7 days before the first dose until 12 weeks after treatment discontinuation. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose; The subject has the ability and willingness to comply with the study protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.排除标准:Exclusion Criteria:
Pulmonary diseases classified as ≥Grade 3 according to NCI-CTCAE v5.0; patients currently diagnosed with interstitial lung disease (ILD); Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.; Active tuberculosis; Patients with active autoimmune diseases; History of other malignancies within 5 years prior to the first dose; HBsAg-positive and/or HBcAb-positive with HBV-DNA levels ≥ the lower limit of detection; HCV antibody-positive with HCV-RNA levels ≥ the lower limit of detection; HIV antibody-positive; Poorly controlled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg); History of severe cardiovascular or cerebrovascular diseases; Patients with a history of hypersensitivity to recombinant humanized antibodies or any excipients of GNC-038; Pregnant or lactating women; Patients with central nervous system involvement; Major surgery within 28 days before the first dose of this study or planned major surgery during the study period; Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT); Autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before initiating GNC-038 treatment; Current use of immunosuppressive therapy; Radiotherapy within 4 weeks before initiating GNC-038 treatment; Chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives prior to treatment; CAR-T therapy within 12 weeks before initiating GNC-038 treatment; Use of any other investigational drug in a clinical trial within 4 weeks or 5 half-lives before the first dose of this study; Any other condition deemed unsuitable for participation in this clinical trial by the investigator.
引自 ClinicalTrials.gov, NCT05623982, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05623982,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。